{"protocolSection":{"identificationModule":{"nctId":"NCT06023095","orgStudyIdInfo":{"id":"18610"},"secondaryIdInfos":[{"id":"J2A-GH-GZGX","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities","officialTitle":"A Multiple Dose Titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Chinese Participants Who Have Obesity or Are Overweight With Weight-related Comorbidities"},"statusModule":{"statusVerifiedDate":"2026-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-09-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-07-29","type":"ACTUAL"},"completionDateStruct":{"date":"2024-07-29","type":"ACTUAL"},"studyFirstSubmitDate":"2023-08-29","studyFirstSubmitQcDate":"2023-08-29","studyFirstPostDateStruct":{"date":"2023-09-05","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-04-30","resultsFirstSubmitQcDate":"2026-06-19","resultsFirstPostDateStruct":{"date":"2026-07-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-06-19","lastUpdatePostDateStruct":{"date":"2026-07-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period."},"conditionsModule":{"conditions":["Overweight","Obesity"],"keywords":["Safety and Tolerability","Chinese","LY3502970"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":24,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"LY3502970 (Cohort 1)","type":"EXPERIMENTAL","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 milligram (mg), 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily (QD) from Day 1 for 16 weeks.","interventionNames":["Drug: LY3502970"]},{"label":"LY3502970 (Cohort 2)","type":"EXPERIMENTAL","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks.","interventionNames":["Drug: LY3502970"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received placebo administered orally QD.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"LY3502970","description":"Administered orally.","armGroupLabels":["LY3502970 (Cohort 1)","LY3502970 (Cohort 2)"]},{"type":"DRUG","name":"Placebo","description":"Administered orally.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration","description":"A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module","timeFrame":"Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2)"}],"secondaryOutcomes":[{"measure":"Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 1)","description":"Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.","timeFrame":"Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)"},{"measure":"Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 2)","description":"Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.","timeFrame":"Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)"},{"measure":"PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 1)","description":"Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.","timeFrame":"Cohort 1: Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)"},{"measure":"PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 2)","description":"Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.","timeFrame":"Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)"},{"measure":"PD: Change From Baseline in Body Mass Index","description":"PD: Change from baseline in Body Mass Index calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Body Mass Index.","timeFrame":"Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)"},{"measure":"Pharmacodynamics (PD): Change From Baseline in Body Weight","description":"PD: Change from baseline in body weight calculated as post-baseline value minus baseline value. Negative values indicate a decrease in body weight.","timeFrame":"Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)"},{"measure":"PD: Change From Baseline in Waist Circumference","description":"PD: Change from baseline in Waist Circumference calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Waist Circumference.","timeFrame":"Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)"},{"measure":"PD: Change From Baseline in Fasting Plasma Glucose","description":"PD: Change From Baseline in Fasting Plasma Glucose calculated as post-baseline value minus baseline value. Negative values indicate a decrease from baseline","timeFrame":"Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Are native Chinese males or females\n* Have had a stable body weight for the 3 months prior to randomization (less than 5% body weight change) and body mass index of ≥ 30.0 kilograms per square meter (kg/m²) or between 27.0 up to 30.0 kg/m² with at least 1 of the following weight-related comorbidities including Hypertension, Dyslipidemia, Cardiovascular disease, Obstructive sleep apnea\n\nExclusion Criteria:\n\n* Have any prior diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or rare forms of diabetes mellitus\n* Have used or intend to use any prescription or over-the-counter medications or traditional Chinese treatments within 3 months prior to screening, exception of medications for the treatment of concurrent medical conditions with a stable dose\n* Have known allergies to GLP-1RAs, LY3502970, related compounds, any components of the formulation, or have a history of significant atopy\n* Are overweight or have obesity induced by other endocrinological disorders, diagnosed monogenetic, or syndromic forms of obesity\n* Have or plan to have a surgical, endoscopic or device-based treatment for obesity\n* Have a history or presence of psychiatric disorder, a moderately severe or severe depression status, or a significantly risk for suicide\n* Have a history of acute or chronic pancreatitis\n* Have a known self or family history of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma\n* Have other acute, chronic, or uncontrolled medical conditions, vital organ failure or abnormal laboratory value in the judgment of the investigator would make the participant inappropriate for entry into this study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Guangdong Provincial People's Hospital","city":"Guangzhou","state":"Guangdong","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"West China Hospital Sichuan University","city":"Chengdu","state":"Sichuan","zip":"610041","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Shanghai General Hospital","city":"Shanghai","state":"Songjiang","zip":"201620","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily (QD) from Day 1 for 16 weeks."},{"id":"FG001","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks."},{"id":"FG002","title":"Placebo","description":"Participants received placebo administered orally QD."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"One participant who received doses of LY3502970 up to 1 mg on Day 29, was discontinued from the study due to a protocol deviation.","numSubjects":"9"},{"groupId":"FG001","comment":"One participant in Cohort 2, who received doses of LY3502970 up to 6 mg on Day 83, was discontinued from the study due to adverse event.","numSubjects":"9"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Protocol Deviation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All enrolled participants.","groups":[{"id":"BG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered QD from Day 1 for 16 weeks."},{"id":"BG001","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks."},{"id":"BG002","title":"Placebo","description":"Participants received placebo administered orally QD."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"24"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.8","spread":"5.2"},{"groupId":"BG001","value":"29.8","spread":"7.6"},{"groupId":"BG002","value":"31.5","spread":"11.0"},{"groupId":"BG003","value":"30.1","spread":"7.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"12"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"12"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"24"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"24"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"24"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration","description":"A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module","populationDescription":"All enrolled participants who receive at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2)","groups":[{"id":"OG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered orally QD from Day 1 for 16 weeks."},{"id":"OG001","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks."},{"id":"OG002","title":"Placebo","description":"Participants received placebo administered orally QD."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"}]}],"classes":[{"title":"TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"}]}]},{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 1)","description":"Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.","populationDescription":"All enrolled participants who received at least 1 dose of study drug and had evaluable PK data for this outcome were included in the analysis; the number of participants analyzed varies by timepoint based on data availability.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram per millilitre (ng/mL)","timeFrame":"Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)","groups":[{"id":"OG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered orally QD from Day 1 for 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"title":"Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":"39"}]}]},{"title":"Day 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":"43"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 2)","description":"Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.","populationDescription":"All enrolled participants who received at least 1 dose of study drug and had evaluable PK data for this outcome were included in the analysis; the number of participants analyzed varies by timepoint based on data availability.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram per millilitre (ng/mL)","timeFrame":"Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)","groups":[{"id":"OG000","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"title":"Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.01","spread":"44"}]}]},{"title":"Day 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":"41"}]}]},{"title":"Day 140","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":"42"}]}]},{"title":"Day 168","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":"41"}]}]}]},{"type":"SECONDARY","title":"PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 1)","description":"Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.","populationDescription":"All enrolled participants who received at least 1 dose of study drug and had evaluable PK data for this outcome were included in the analysis; the number of participants analyzed varies by timepoint based on data availability.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram *hour per milliliter (ng*h/mL)","timeFrame":"Cohort 1: Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)","groups":[{"id":"OG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered orally QD from Day 1 for 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"title":"Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"266","spread":"26"}]}]},{"title":"Day 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1010","spread":"26"}]}]}]},{"type":"SECONDARY","title":"PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 2)","description":"Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.","populationDescription":"All enrolled participants who receive at least 1 dose of study drug and had evaluable PK data for this outcome were included in the analysis; the number of participants analyzed varies by timepoint based on data availability.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram *hour per milliliter (ng*h/mL)","timeFrame":"Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)","groups":[{"id":"OG000","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"title":"Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":"42"}]}]},{"title":"Day 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"520","spread":"37"}]}]},{"title":"Day 140","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1650","spread":"33"}]}]},{"title":"Day 168","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2620","spread":"40"}]}]}]},{"type":"SECONDARY","title":"PD: Change From Baseline in Body Mass Index","description":"PD: Change from baseline in Body Mass Index calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Body Mass Index.","populationDescription":"All enrolled participants who receive at least 1 dose of study drug and had evaluable PD data for this outcome.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilograms per square meter (kg/m²)","timeFrame":"Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)","groups":[{"id":"OG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered orally QD from Day 1 for 16 weeks."},{"id":"OG001","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks."},{"id":"OG002","title":"Placebo (Cohort 1)","description":"Participants received placebo for 16 weeks."},{"id":"OG003","title":"Placebo (Cohort 2)","description":"Participants received placebo for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3046","spread":"1.1819"},{"groupId":"OG001","value":"-3.5964","spread":"1.4441"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"Summary statistics were not calculated due to the small sample size (n=2); therefore, individual participant data are reported.\n\nThe individual change-from-baseline values are --1.134 kg/m² (minimum) and 0.258 kg/m² (maximum)."},{"groupId":"OG003","value":"NA","spread":"NA","comment":"Summary statistics were not calculated because only one participant (n=1) was included; therefore, individual participant data are reported.\n\nThe individual change-from-baseline value is -1.394 kg/m²"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics (PD): Change From Baseline in Body Weight","description":"PD: Change from baseline in body weight calculated as post-baseline value minus baseline value. Negative values indicate a decrease in body weight.","populationDescription":"All enrolled participants who receive at least 1 dose of study drug and had evaluable PD data for this outcome.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilograms (kg)","timeFrame":"Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)","groups":[{"id":"OG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered orally QD from Day 1 for 16 weeks."},{"id":"OG001","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks."},{"id":"OG002","title":"Placebo (Cohort 1)","description":"Participants received placebo for 16 weeks"},{"id":"OG003","title":"Placebo (Cohort 2)","description":"Participants received placebo for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.156","spread":"3.710"},{"groupId":"OG001","value":"-10.211","spread":"4.011"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"Summary statistics were not calculated due to the small sample size (n=2); therefore, individual participant data are reported.\n\nThe individual change-from-baseline values are --3.05 kg (minimum) and 0.80 kg (maximum)."},{"groupId":"OG003","value":"NA","spread":"NA","comment":"Summary statistics were not calculated because only one participant (n=1) was included; therefore, individual participant data are reported.\n\nThe individual change-from-baseline value is 3.75 kg."}]}]}]},{"type":"SECONDARY","title":"PD: Change From Baseline in Waist Circumference","description":"PD: Change from baseline in Waist Circumference calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Waist Circumference.","populationDescription":"All enrolled participants who receive at least 1 dose of study drug and had evaluable PD data for this outcome.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"centimeters (cm)","timeFrame":"Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)","groups":[{"id":"OG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered orally QD from Day 1 for 16 weeks."},{"id":"OG001","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks."},{"id":"OG002","title":"Placebo (Cohort 1)","description":"Participants received placebo for 16 weeks."},{"id":"OG003","title":"Placebo (Cohort 2)","description":"Participants received placebo for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.778","spread":"2.879"},{"groupId":"OG001","value":"-11.667","spread":"3.466"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"Summary statistics were not calculated due to the small sample size (n=2); therefore, individual participant data are reported.\n\nThe individual change-from-baseline values are -4.50 cm (minimum) and 0.25 cm (maximum)."},{"groupId":"OG003","value":"NA","spread":"NA","comment":"Summary statistics were not calculated because only one participant (n=1) was included; therefore, individual participant data are reported.\n\nThe individual change-from-baseline value is -5.00 cm."}]}]}]},{"type":"SECONDARY","title":"PD: Change From Baseline in Fasting Plasma Glucose","description":"PD: Change From Baseline in Fasting Plasma Glucose calculated as post-baseline value minus baseline value. Negative values indicate a decrease from baseline","populationDescription":"All enrolled participants who receive at least 1 dose of study drug and had evaluable PD data for this outcome.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimoles per liter (mmol/L)","timeFrame":"Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)","groups":[{"id":"OG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered orally QD from Day 1 for 16 weeks."},{"id":"OG001","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks."},{"id":"OG002","title":"Placebo (Cohort 1)","description":"Participants received placebo for 16 weeks."},{"id":"OG003","title":"Placebo (Cohort 2)","description":"Participants received placebo for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.45"},{"groupId":"OG001","value":"-0.17","spread":"0.28"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"Summary statistics were not calculated due to the small sample size (n=2); therefore, individual participant data are reported.\n\nThe individual change-from-baseline values are -0.2 mmol/L (minimum) and 0 mmol/L (maximum)."},{"groupId":"OG003","value":"NA","spread":"NA","comment":"Summary statistics were not calculated because only one participant (n=1) was included; therefore, individual participant data are reported.\n\nThe individual change-from-baseline value is 0.1 mmol/L."}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline up to 182 Days","description":"All enrolled participants who receive at least 1 dose of study drug or placebo. Participants were analyzed according to the intervention they actually received.","eventGroups":[{"id":"EG000","title":"LY3502970 (Cohort 1)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg and then 12 mg LY3502970 administered orally QD from Day 1 for 16 weeks.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10},{"id":"EG001","title":"LY3502970 (Cohort 2)","description":"Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10},{"id":"EG002","title":"Placebo","description":"Participants received placebo administered orally QD.","deathsNumAffected":0,"deathsNumAtRisk":4,"seriousNumAffected":0,"seriousNumAtRisk":4,"otherNumAffected":3,"otherNumAtRisk":4}],"otherEvents":[{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":4}]},{"term":"Atrioventricular block first degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Ocular hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":10},{"groupId":"EG001","numEvents":14,"numAffected":5,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":10},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Aphthous ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":6,"numAtRisk":10},{"groupId":"EG001","numEvents":16,"numAffected":7,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Faeces hard","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":10,"numAffected":5,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Frequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Infrequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":10},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Regurgitation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":4,"numAtRisk":10},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hypertransaminasaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Asymptomatic bacteriuria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":10},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":10},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":4}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Electrocardiogram q wave abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Electrocardiogram st segment abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Electrocardiogram t wave abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Electrocardiogram t wave alternans","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Granulocyte count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Lymphocyte count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Monocyte count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Protein urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":10},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":4}]},{"term":"Urobilinogen urine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":10},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":10},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":4}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":10},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Soft tissue disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Initial insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Terminal insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Heavy menstrual bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":4}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"08005455979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2024-03-15","uploadDate":"2026-04-16T17:07","filename":"Prot_000.pdf","size":12542215},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-06-18","uploadDate":"2026-04-16T17:07","filename":"SAP_001.pdf","size":866701}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D050177","term":"Overweight"},{"id":"D009765","term":"Obesity"}],"ancestors":[{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000729680","term":"orforglipron"}]}},"hasResults":true}